Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
- Resource Type
- Authors
- Robert B. Couch; Krishna Narayanan; Xinrong Tao; Chien Te K. Tseng; Bi Hung Peng; Abdullah Algaissi; Anurodh S. Agrawal; Tania Garron
- Source
- Human Vaccines & Immunotherapeutics
- Subject
- 0301 basic medicine
Middle East respiratory syndrome coronavirus
medicine.medical_treatment
viruses
Immunology
Short Report
Mice, Transgenic
medicine.disease_cause
Antibodies, Viral
Virus
03 medical and health sciences
0302 clinical medicine
Immunopathology
medicine
Hypersensitivity
Immunology and Allergy
Animals
Neutralizing antibody
Lung
Coronavirus
Pharmacology
biology
business.industry
virus diseases
Viral Vaccines
biochemical phenomena, metabolism, and nutrition
respiratory system
Virology
Antibodies, Neutralizing
3. Good health
respiratory tract diseases
Vaccination
030104 developmental biology
Immunization
Vaccines, Inactivated
030220 oncology & carcinogenesis
biology.protein
Middle East Respiratory Syndrome Coronavirus
business
Coronavirus Infections
Adjuvant
- Language
- ISSN
- 2164-554X
2164-5515
To determine if a hypersensitive-type lung pathology might occur when mice were given an inactivated MERS-CoV vaccine and challenged with infectious virus as was seen with SARS-CoV vaccines, we prepared and vaccinated mice with an inactivated MERS-CoV vaccine. Neutralizing antibody was induced by vaccine with and without adjuvant and lung virus was reduced in vaccinated mice after challenge. Lung mononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in the vaccine groups. Inactivated MERS-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS-CoV infection that is similar to that found with inactivated SARS-CoV vaccines from SARS-CoV infection.